Comments
Strides Shasun has received approval to manufacture the generic version of Sofosbuvir 400 mg tablet from Drug Controller General of India.
Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for Hepatitis C treatment and represents a paradigm shift in the existing Hepatitis C cure. The product will continue to be marketed under the brand name ‘Virso’ in India and overseas, the company said in a statement to the exchanges.
In September 2014, Strides entered into a licensing agreement with Gilead Sciences, to bring Hepatitis C cure to 91 developing countries. Globally, it is estimated that 170-185 million people are chronically infected with Hepatitis C virus (HCV). In India, it is estimated that 12-18 million patients are infected with Hepatitis C, which is several fold greater than those with HIV/AIDS. This drug in combination therapy has shown to have high cure rates of around 90 per cent, according to industry watchers.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.